Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9526310.26442/20751753.2020.6.200327ArticlesСтатьиReview ArticleVaginal dryness and quality of life in mature womenВагинальная сухость и качество жизни у женщин зрелого возрастаKuznetsovaIrina V.КузнецоваИрина Всеволодовна

д-р мед. наук, проф., рук. направления

ms.smith.ivk@gmail.comHigher Medical SchoolНОЧУ ДПО «Высшая медицинская школа»15062020226VOL 22, NO6 (2020)ТОМ 22, №6 (2020)91428122021Copyright ©; 2020, Consilium MedicumCopyright ©; 2020, ООО "Консилиум Медикум"2020Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/95263

The issue of maintaining the quality of life in aging women remains relevant, especially in light of the nationwide concept of active aging. Sexuality is one of the important components of the quality of life of pre-menopausal and post-menopausal women, and sexual dysfunction is an important factor that reduces the quality of life. Sexual dysfunction is considered as a part of genitourinary syndrome of menopause (GSM), and in the transition period of a woman's life, it most commonly occurs due to vulvovaginal atrophy. Consequently, the diagnosis and treatment of sexual dysfunction in peri- and postmenopausal women is usually related to diagnosis and therapy of GSM. The analytic review examines the epidemiology, diagnosis and treatment of symptoms of vulvovaginal atrophy with an emphasis on vaginal dryness as the most frequent and early symptom of the disease, on the one hand, and the main cause of sexual dysfunction in menopausal women, on the other. Standard and auxiliary methods of therapy are proposed, which, when combined, can provide an improvement in the quality of sexual life with simultaneous prevention of GSM progression. Key words: menopause, genitourinary syndrome of menopause, vulvovaginal atrophy, vaginal dryness, sexual dysfunction, topical estrogens, lubricants, moisturizers for vaginal use. For citation: Kuznetsova I.V. Vaginal dryness and quality of life in mature women. Consilium Medicum. 2020; 22 (6): 9-14. DOI: 10.26442/20751753.2020.6.200327

Проблема сохранения качества жизни у стареющих женщин остается актуальной, особенно в свете принятой на государственном уровне концепции активного долголетия. Одним из важных компонентов качества жизни женщин в возрасте перименопаузы и постменопаузы является сексуальность, а существенным фактором снижения качества жизни становятся сексуальные расстройства. Нарушения сексуальной функции рассматриваются в рамках генитоуринарного синдрома (ГУМС), и в переходном периоде жизни женщины они чаще всего возникают в результате формирования вульвовагинальной атрофии. Следовательно, диагностика и терапия сексуальных расстройств у женщин в пери- и постменопаузе обычно лежат в плоскости диагностики и терапии ГУМС. В аналитическом обзоре рассматриваются вопросы эпидемиологии, диагностики и методов лечения симптомов вульвовагинальной атрофии с акцентом на сухость влагалища как наиболее частый и ранний признак заболевания, с одной стороны, и главная причина сексуальных нарушений у женщин менопаузального возраста - с другой. Предлагаются стандартные и вспомогательные методы терапии, которые при комплексном применении способны обеспечить улучшение качества сексуальной жизни с одновременной профилактикой прогрессирования ГУМС. Ключевые слова: менопауза, генитоуринарный менопаузальный синдром, вульвовагинальная атрофия, сухость влагалища, сексуальные нарушения, топические эстрогены, лубриканты, увлажняющие средства для вагинального применения. Для цитирования: Кузнецова И.В. Вагинальная сухость и качество жизни у женщин зрелого возраста. Consilium Medicum. 2020; 22 (6): 9-14. DOI: 10.26442/20751753.2020.6.200327

menopausegenitourinary syndrome of menopausevulvovaginal atrophyvaginal drynesssexual dysfunctiontopical estrogenslubricantsmoisturizers for vaginal useменопаузагенитоуринарный менопаузальный синдромвульвовагинальная атрофиясухость влагалищасексуальные нарушениятопические эстрогенылубрикантыувлажняющие средства для вагинального примененияPalacios S, Henderson VW, Siseles N et al. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric 2010; 13: 419-28.Monteleone P, Mascagni G, Giannini A et al. Symptoms of menopause - global prevalence, physiology and implications. Nat Rev Endocrinol 2018; 14: 199-215.Davis SR, Lambrinoudaki I, Lumsden M et al. Menopause. Nat Rev Dis Primers. 2015; 1: 15004.Levine ME, Lu AT, Chen BH et al. Menopause accelerates biological aging. Proc Natl Acad Sci USA 2016;113:9327-32.Palacios S, Castelo-Branco C, Currie H et al. Update on management of genitourinary syndrome of menopause: a practical guide. Maturitas 2015; 82: 308-13.Donders GGG, Ruban K, Bellen G, Grinceviciene S. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019; 20: 821-35.Stika CS. Atrophic vaginitis. Dermatol Ther 2010; 23: 514-22.Brauer MM, Smith PG. Estrogen and female reproductive tract innervation: cellular and molecular mechanisms of autonomic neuro plasticity. Auton Neurosci 2015; 187: 1-17.Griebling TL, Liao Z, Smith PG. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause 2012; 19: 630-5.The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause 2013; 20 (9): 888-902.Portman DJ, Gass MLS. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Maturitas 2014; 79(3): 349-54.Thurston RC. Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric 2018; 21: 96-100.Avis NE, Crawford SL, Green R. Vasomotor symptoms across the menopause transition: differences among women. Obstet Gynecol Clin North Am 2018; 45: 629-40.Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause 2018; 25: 1331-8.Nappi RE, Murina F, Perrone G et al. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Ginecol 2017; 69: 370-80.Mitchell CM, Waetjen LE. Genitourinary changes with aging. Obstet Gynecol Clin North Am 2018; 45: 737-50.Calleja-Aqius J, Brincat MP. The urogenital system and the menopause. Climacteric 2015; 18 (1): 18-22.Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J 2015; 26 (1): 15-28.Palacios S, Nappi RE, Bruyniks N et al; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 2018; 21: 286-91.Parish SJ, Nappi RE, Krychman ML et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013; 5: 437-47.Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric 2012; 15: 36-44.Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010; 67: 233-8.Nappi RE, Palacios S, Particco M, Panay N. The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: country-specific comparisons of postmenopausal women's perceptions, experiences and needs. Maturitas 2016; 91: 81-90.Krychman M, Graham S, Bernick B et al. The women's EMPOWER survey: women's knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med 2017;14:425-33.Faubion SS, Larkin LC, Stuenkel CA et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 2018;25:596-608.Sadovsky R, Basson R, Krychman M et al. Cancer and sexual problems. J Sex Med 2010; 7: 349-73.Nappi RE, Cucinella L, Martini E et al. Sexuality in premature ovarian insufficiency. Climacteric 2019; 22: 289-95.Doumouchtsis SK, Chrysanthopoulou EL. Urogenital consequences in ageing women. Best Pract Res Clin Obstet Gynaecol 2013; 27: 699-714.Stiles M, Redmer J, Paddock E, Schrager S. Gynecologic issues in geriatric women. J Womens Health 2012; 21: 4-9.Thomas HN, Hess R, Thurston RC. Correlates of sexual activity and satisfaction in midlife and older women. Ann Fam Med 2015; 13: 336-42.Nappi RE, Albani F, Santamaria V et al. Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas 2010; 67: 78-83.Nappi RE, Seracchioli R, Salvatore S et al. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol 2019; 35: 453-9.Panay N, Palacios S, Bruyniks N et al; EVES Study Investigators. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas 2019; 124: 55-61.Nappi RE, Biglia N, Cagnacci A et al. Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecol Endocrinol 2016; 32: 602-6.Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med 2013; 10: 1567-74.Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc 2017; 92 (12): 1842-9.The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24 (7): 728-53.Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016; 31: CD001500.American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol 2014; 123 (1): 202-16.Naumova I, Castelo-Branco C. Current treatment options for postmenopausal vaginal atrophy. Int J Womens Health 2018; 10: 387-95.Caruso S, Cianci S, Amore FF et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause 2016; 23 (1): 47-54.Mueck AO, Ruan X, Prasauskas V et al. Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric 2018; 21 (2): 140-7.Kingsberg SA, Larkin L, Krychman M et al. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause 2019; 26 (2): 124-31.Bruyniks N, Nappi RE, Castelo-Branco C et al. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric 2016; 19: 60-5.Eden J. Managing menopausal symptoms after breast cancer. Eur J Endocrinol 2016; 174: R71-R77.Mazzarello S, Hutton B, Ibrahim MF et al. Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials. Breast Cancer Res Treat 2015;152:1-8.Hickey M, Marino J, Braat S, Wong S. A randomized, double-blind, crossover trial comparing a sili-cone-versus water-based lubricant for sexual discomfort after breast cancer. Breast Cancer Res Treat 2016; 158: 79-90.Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric 2016; 19: 151-61.Takacs P, Kozma B, Erdodi B et al. Zinc-containing Vaginal Moisturizer Gel Improves Postmenopausal Vulvovaginal Symptoms: A Pilot Study. J Menopausal Med 2019; 25 (1): 63-8. DOI: 10.6118/jmm.2019.25.1.63Lee Y, Chung H, Kim J et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011; 117: 922-7.Carati D, Zizza A, Guido M et al. Safety, efficacy, and tolerability of differential treatment to prevent and treat vaginal dryness and vulvovaginitis in diabetic women. Clin Exp Obstet Gynecol 2016; 43 (2): 198-202.Stute P, May TW, Masur C et al. Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial. Climacteric 2015; 18 (4): 582-9. DOI: 10.3109/13697137.2015.1036854Mitchell CM, Reed SD, Diem S et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial. JAMA Intern Med 2018; 178 (5): 681-90. DOI: 10.1001/jamainternmed.2018.0116Gibson CJ, Huang AJ, Larson JC et al. Patient-centered change in the day-to-day impact of postmenopausal vaginal symptoms: results from a multicenter randomized trial. Am J Obstet Gynecol 2020; 223 (1): 99.e1-99.e9. DOI: 10.1016/j.ajog.2019.12.270Lukas VA, Simon JA. MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence. Menopause 2020; 27 (6): 722-5. DOI: 10.1097/GME.0000000000001516